Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 2, 2009, Pages 109-130

  Mani, Sridhar ^a,b   Ghalib, Mohammed ^a,b   Chaudhary, Imran ^a,b   Goel, Sanjay ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Medicine Oncology and Molecular Genetics   (United States)

Author keywords

Drug metabolism; Orphan nuclear receptors; Pharmacokinetic pharmacodynamic relationships; Pregnane X receptor; Transcriptional regulation

Indexed keywords

5 ETHYNYLURACIL; CAFFEINE; CYCLOSPORIN; DICLOFENAC; ELACRIDAR; FLUOROURACIL; GLYCOPROTEIN P; HYPERFORIN; IRINOTECAN; IXABEPILONE; KETOCONAZOLE; MERCAPTOPURINE; METHOTREXATE; MORPHINE 6 GLUCURONIDE; PACLITAXEL; PARACETAMOL; PAROXETINE; PHENYTOIN; QUINIDINE; RIFAMPICIN; SORIVUDINE; STEROID; TAMOXIFEN; TARIQUIDAR; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VALSPODAR; VERAPAMIL; VINBLASTINE; XEMPRA;

BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN CANCER; BREAST CANCER; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG TRANSPORT; ENZYME INHIBITION; ENZYME SUBSTRATE; FOOD; GASTROINTESTINAL SYMPTOM; GENETIC TRANSCRIPTION; HUMAN; HYPERICUM PERFORATUM; LEUKEMIA; LOW DRUG DOSE; NEUROPATHY; OUTCOME ASSESSMENT; PREDICTION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; POLYPHARMACY; QUALITY OF LIFE; TRANSCRIPTION, GENETIC;

EID: 67649133610     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902753212     Document Type: Review

References (117)

1. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998;4(9):2039-2045 (Pubitemid 28415645)
2. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results. Anticancer Res 1994;14(6A):2347-2352
3. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15(4):1502-1510 (Pubitemid 27167386)
4. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7(11):1748-1756 (Pubitemid 19272848)
5. Petros WP, Hopkins PJ, Spruill S, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005;23(25):6117-6125 (Pubitemid 46300229)
6. Riechelmann RP, Krzyzanowska MK. Issues of potential drug interactions and prescription duplication among patients with cancer. Am J Hemtol Oncol 2007;6(9):529-531 (Pubitemid 47584188)
7. Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007;99:592-600 (Pubitemid 47073540)
8. Grymonpre RE, Mitenko PA, Sitar DS, et al. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 1988;36:1092-1098 (Pubitemid 19005050)
9. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 1998;18:1112-1120 (Pubitemid 28439998)
10. Mannisto PT, Mantyla R, Nykanen S, et al. Impairing effect of food on ketoconazole absorption. Antimicrob Agents Chemother 1982;21(5):730-733
11. Lelawongs P, Barone JA, Colaizzi JL, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988;7(3):228-235 (Pubitemid 18099510)
12. Shepard DR, Mani S, Kastrissios H, et al. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol 2002;49(5):398-402 (Pubitemid 34439341)
13. Schilsky RL, Bukowski R, Burris H 3rd, et al. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol 2000;11(4):415-420
14. Mani S, Hochster H, Beck T, et al. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2000;18(15):2894-2901 (Pubitemid 30620078)
15. Cao S, Baccanari DP, Joyner SS, et al. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cancer Res 1995;55(24):6227-6230
16. Baker SD, Khor SP, Adjei AA, et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996;14(12):3085-3096 (Pubitemid 26408801)
17. Kaplan RH, Weirnik PH. Neurotoxicity of anti-tumor agents. In: Perry MC, Yarbro JW, editors, Toxicity of Chemotherapy, Orlando, FL Grune and Stratton, 365-374
18. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1(3):223-236 (Pubitemid 44244128)
19. Gavins F, Yilmaz G, Granger DN. The evolving paradigm for blood cell-endothelial cell interactions in the cerebral microcirculation. Microcirculation 2007;14(7):667-681 (Pubitemid 47434284)
20. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6(8):650-661 (Pubitemid 47202487)
21. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007;24(9):1745-1758 (Pubitemid 47206624)
22. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007;25(16):2306-2312 (Pubitemid 46954659)
23. Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 2004;66(3):413-419 (Pubitemid 39329239)
24. Bauer B, Yang X, Hartz AM, et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 2006;70(4):1212-1219
25. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36:57-104 (Pubitemid 38387835)
26. Ferry DR. Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int J Clin Pharmacol Ther 1998;36(1):29-40 (Pubitemid 28031806)
27. Oza AM. Clinical development of P glycoprotein modulators in oncology. Novartis Found Symp 2002;243:103-15; discussion 115-8, 180-185
28. Rodrigues AD. Drug-Drug Interactions. Second edition. In: Drugs and the Pharmaceutical Sciences V. 179, Informa Healthcare USA, Inc., New York, NY 10017; 2008. p. 579
29. Robert J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur J Clin Invest 1999;29(6):536-545 (Pubitemid 29271645)
30. Chen J, Balmaceda C, Bruce JN, et al. Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol 2006;76(1):85-92 (Pubitemid 43115765)
31. Kemper EM, van Zandbergen AE, Cleypool C, et al. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 2003;9(7):2849-2855 (Pubitemid 36842131)
32. Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110(9):1309-1318 (Pubitemid 35285757)
33. Lötsch J, Schmidt R, Vetter G, et al. Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem 2002;83(2):241-248 (Pubitemid 35191390)
34. Drewe J, Ball HA, Beglinger C, et al. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 2000;50(3):237-246 (Pubitemid 30701419)
35. Rautio J, Humphreys JE, Webster LO, et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006;34(5):786-792
36. Huang SM, Reynolds KS, Strong JM, et al. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008;38(7-8):709-724
37. Huang H, Wang H, Sinz M, et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007;26(2):258-268 (Pubitemid 46095736)
38. Wang H, Huang H, Li H, et al. Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res 2007;13(8):2488-2495 (Pubitemid 46698601)
39. Okuda H, Nishiyama T, Ogura K, et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 1997;25(2):270-273 (Pubitemid 27086129)
40. Yan J, Tyring SK, McCrary MM, et al. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clin Pharmacol Ther 1997;61(5):563-573 (Pubitemid 27261760)
41. Diasio RB. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 1998;46(1):1-4 (Pubitemid 28308417)
42. Goel S, Cohen M, Cömezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res 2008;14(9):2701-2709
43. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1734-5,1758-1764 (Pubitemid 38008898)
44. Henry NL, Stearns V, Flockhart DA, et al. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165(10):1251-1255
45. Sane RS, Buckley DJ, Buckley AR, et al. Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells. Drug Metab Dispos 2008;36(5):946-954 (Pubitemid 351574894)
46. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol 2008. [Epub ahead of print]
47. Hu Z, Yang X, Ho PC, et al. St. John's wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res 2005;22:902-914
48. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-1249 (Pubitemid 34993875)
49. Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-329
50. Smith P, Bullock JM, Booker BM, et al. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24:1508-1514
51. Komoroski BJ, Parise RA, Egorin MJ, et al. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 2005;11:6972-6979
52. Watkins RE, Maglich JM, Moore LB, et al. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 2003;42(6):1430-1438
53. Hu ZP, Yang XX, Chen X, et al. A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. Curr Drug Metab 2007;8(2):157-171 (Pubitemid 46218682)
54. DiPetrillo K, Wood S, Kostrubsky V, et al. Effect of caffeine on acetaminophen hepatotoxicity in cultured hepatocytes treated with ethanol and isopentanol. Toxicol Appl Pharmacol 2002;185(2):91-97 (Pubitemid 36062799)
55. Hazai E, Vereczkey L, Monostory K. Reduction of toxic metabolite formation of acetaminophen. Biochem Biophys Res Commun 2002;291(4):1089-1094 (Pubitemid 34694385)
56. Cameron MD, Wen B, Roberts AG, et al. Cooperative binding of acetaminophen and caffeine within the P450 3A4 active site. Chem Res Toxicol 2007;20(10):1434-1441 (Pubitemid 350057212)
57. Wolf KK, Wood SG, Hunt JA, et al. Role of the nuclear receptor pregnane X receptor in acetaminophen hepatotoxicity. Drug Metab Dispos 2005;33(12):1827-1836 (Pubitemid 41697268)
58. Ricketts ML, Boekschoten MV, Kreeft AJ, et al. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. Mol Endocrinol 2007;21(7):1603-1616 (Pubitemid 47001085)
59. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther 2004;309(1):226-234 [Epub 2004 Jan 13] (Pubitemid 38393134)
60. Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64(16):5804-5811 (Pubitemid 39095580)
61. van der Heijden JW, AC Dijkmans B, Scheper RJ, Jansen G. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs - from bench to bedside. Nat Clin Pract Rheumatol 2007;3:26-34 (Pubitemid 46251742)
62. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther 2004;309(1):226-234 (Pubitemid 38393134)
63. Uwai Y, Taniguchi R, Motohashi H, et al. Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet 2004;19(5):369-374
64. Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002;303(2):534-539 (Pubitemid 35231223)
65. Joerger M, Huitema AD, van den Bongard HJ, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006;62(1):71-80 (Pubitemid 44195244)
66. Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64(16):5804-5811 (Pubitemid 39095580)
67. Wu H, Horton JR, Battaile K, et al. Structural basis of allele variation of human thiopurine-S-methyltransferase. Proteins 2007;67:198-208 (Pubitemid 46340139)
68. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126(8):608-614 (Pubitemid 27172187)
69. Marra C, Esdaile J, Aslam HA. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002;29:2507-2512 (Pubitemid 35416953)
70. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002;29(12):2507-2512 (Pubitemid 35416953)
71. Reuther LO, Sonne J, Larsen NE, et al. Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol 2003;38(9):972-977 (Pubitemid 37153627)
72. Reuther LO, Vainer B, Sonne J, Larsen NE. Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol 2004;59(11):797-801 (Pubitemid 38221656)
73. Wikipedia entry on thiopurine methyltransferase. Available from: http://en.wikipedia.org/wiki/Thiopurine-methyltransferase
74. TPMT ImmunoAssay Kit Online Store. Available from: http://www.tpmtassay. com/store/
75. Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62(17):4955-4962 (Pubitemid 34984419)
76. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348(15):1442-1448 (Pubitemid 36407173)
77. Yamaguchi H, Hishinuma T, Endo N, et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int J Gynecol Cancer 2006;16(3):979-985 (Pubitemid 43886713)
78. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97(7):3473-3478 (Pubitemid 30183327)
79. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841-850 (Pubitemid 26006526)
80. Blumberg B, Sabbagh W Jr, Juguilon H, et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998;12:3195-3205 (Pubitemid 28496264)
81. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998;95:12208-12213 (Pubitemid 28483744)
82. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-1023 (Pubitemid 28419246)
83. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001;7:584-590 (Pubitemid 32448326)
84. Goodwin B, Moore LB, Stoltz CM, et al. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001;60:427-431 (Pubitemid 32781548)
85. Chen Y, Ferguson SS, Negishi M, et al. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 2004;308:495-501 (Pubitemid 38134210)
86. Sonoda J, Xie W, Rosenfeld JM, et al. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci USA 2002;99:13801-13806 (Pubitemid 35215461)
87. Xie W, Yeuh MF, Radominska-Pandya A, et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 2003;100:4150-4155 (Pubitemid 36418172)
88. Falkner KC, Pinaire JA, Xiao GH, et al. Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol Pharmacol 2001;60:611-619 (Pubitemid 32781569)
89. Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002;277:2908-2915 (Pubitemid 34953324)
90. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002;23:687-702 (Pubitemid 35191629)
91. Choudhuri S, Valerio LG. Usefulness of studies on the molecular mechanism of action of herbals/botanicals: the case of St. John's wort. J Biochem Mol Toxicol 2005;19:1-11 (Pubitemid 40315385)
92. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through
93. Watkins RE, Maglich JM, Moore LB, et al. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 2003;42:1430-1438
94. Ueda A, Hamadeh HK, Webb HK, et al. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol Pharmacol 2002;61:1-6 (Pubitemid 34049505)
95. Wei P, Zhang J, Egan-Hafley M, et al. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000;407:920-923 (Pubitemid 30794334)
96. Kakizaki S, Yamamoto Y, Ueda A, et al. Phenobarbital induction of drug/steroid-metabolizing enzymes and nuclear receptor CAR. Biochim Biophys Acta 2003;1619:239-242 (Pubitemid 36160602)
97. Burk O, Arnold KA, Geick A, et al. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol Chem 2005;386:503-513 (Pubitemid 41447572)
98. Schmiedlin-Ren P, Thummel KE, Fisher JM, et al. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3. Mol Pharmacol 1997;51:741-754 (Pubitemid 27224679)
99. Drocourt L, Ourlin JC, Pascussi JM, et al. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 2002;277:25125-25132 (Pubitemid 34951818)
100. Adachi R, Honma Y, Masuno H, et al. Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J Lipid Res 2005;46:46-57 (Pubitemid 40066670)
101. Kostrubsky VE, Lewis LD, Strom SC, et al. Induction of cytochrome P4503A by Taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 1998;355:131-136 (Pubitemid 28364360)
102. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30:795-804 (Pubitemid 34671092)
103. Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 2000;153:1-10 (Pubitemid 30945570)
104. Xie W, Barwick JL, Downes M, et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000;406:435-439 (Pubitemid 30625566)
105. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002;1:259-266 (Pubitemid 37361442)
106. Zhou C, Tabb MM, Sadatrafiei A, et al. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 2004;32:1075-1082
107. Chrencik JE, Orans J, Moore LB, et al. Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol 2005;19(5):1125-1134 (Pubitemid 40594113)
108. Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001;292(5525):2329-2333 (Pubitemid 32568055)
109. Mu Y, Zhang J, Zhang S, et al. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther 2006;316(3):1369-1377 (Pubitemid 43345314)
110. Chan TY. Interaction between warfarin and danshen (Silvia Miltiorrhiza). Ann Pharmacotherapy 2001;35(4):501-504 (Pubitemid 32260218)
111. The Herb Research Foundation: Herb Information Greenpaper on the Ephedra site. Available from: http://www.ephedra.nu/medicine-2.html
112. Gollamudi R, Gupta D, Goel S, Mani S. Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism. Curr Drug Metab 2008;9(7):611-613
113. Cova D, Lorusso V, Silvestris N. The pharmacokinetics and pharmacodynamics of drugs in elderly cachectic (cancer) patients. In: Mantovanni G, editor, cachexia and wasting: A modern approach. DOI: 10.1007/978-88-470- 0552-555, Springer Milan; 2006
114. Lehár J, Zimmermann GR, Krueger AS, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 2007;3:80 (Pubitemid 46360996)
115. Yeh P, Kishnoy R. Networks from drug-drug surfaces. Mol Sys Biol 2007;3:85 (Pubitemid 46350686)
116. Ekins S, Andreyev S, Ryabov A, et al. A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos 2006;34(3):495-503 [Epub 2005 Dec 28] (Pubitemid 43290909)
117. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008;300(24):2867-2878